Tag Archives: neurotherapeutics

Roche Hits First Two of Three

Roche had been approaching a Trifecta of datasets and decision points that would determine whether their steadfast focus on innovative R&D in neuroscience would be sustained. Now, it seems certain that it will be, because the Company had success in … Continue reading

Posted in Big Pharma | Tagged , , , , , , | Leave a comment

Weather Update

The National Weather Service reports that there are some breaks in the thick layer of clouds and fog which has covered the CNS space for much of the past year. While there are not yet clear signs of a summer … Continue reading

Posted in Big Pharma, Biotech, Science | Tagged , , , , | Leave a comment


In the May issue of NeuroPerspective, there was a sidebar entitled ‘Triage Time at Targacept,’ written in the wake of what has undoubtedly been the most trying time in that Company’s history. The sidebar ended with this: “Now Targacept is … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment

The Endangered Species Act of 2012

No, we do not refer to darter fish, the Algerian Ribbed Newt, or Macgregor’s Skink. Those species are thriving compared to NIR’s roster of endangered species, which includes neuro-Sellside Analysts and neuro-IPOs. While there have been rumors of sightings in … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment

The New York Times Sunday Review Welcomes You to the Pleasuredome

NIR is not particularly prone to media paranoia, the notion that there are hidden, manipulative agendas behind stories and opinion pieces. But we are starting to wonder about the NYT Sunday Review. For the second time in three weeks, they … Continue reading

Posted in Muddled Media | Tagged , , , | Leave a comment

Bexarotene Furor

Last week’s publication in Science of a paper by Cramer et al on the effects of bexarotene in transgenic mouse models of Alzheimer’s stirred up quite the media storm, and a flurry of requests from AD families for off-label prescriptions … Continue reading

Posted in Science | Tagged , , , , | 6 Comments

Shrinkage from A to Z

No wonder AstraZeneca‘s CFO did a twenty minute infomercial at JPM on ‘Why you should partner with AstraZeneca.’ Those who have advocated for the transition of Big Pharma to a purely late-stage drug development and commercialization role, leaving R&D to … Continue reading

Posted in Big Pharma | Tagged , , , | 3 Comments